Key result
Review outlines SAPIEN 3 THV procedural advances, complication trends, and future developments for severe AS.
This review summarizes the technology, procedural advances, and complication trends associated with the Edwards SAPIEN 3 transcatheter heart valve for severe aortic stenosis.
SAPIEN 3 review consolidates TAVR insights for severe AS; leaves open prospective validation of trends and future iterations.
Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. The efficacy and safety have been demonstrated in large randomized trials in patients with high- or intermediate operative risk. With latest-generation transcatheter heart valve (THV) systems, growing operator experience and improved patient selection, clinical outcome has significantly improved with a decline of TAVI-related complications. In this review, the Edwards SAPIEN 3 THV is discussed in terms of technology, procedural advances and complication trends and future developments.
No takes yet. Share an insight, caveat, or question.
Rheude et al. (2018) conducted a review in severe aortic stenosis. Edwards SAPIEN 3 transcatheter heart valve was evaluated. The Edwards SAPIEN 3 transcatheter heart valve is reviewed regarding its technology, procedural advances, complication trends, and future developments for treating severe aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: